Nanjing Medlander Medical Technology Co.,Ltd. (SHA:688273)
China · Delayed Price · Currency is CNY 29.48
+0.05 (0.17%)
Sep 28, 2026, 4:00 PM EDT
SHA:688273 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,883 | 4,159 | 2,287 | 3,352 | 3,260 | - | |
Market Cap Growth | -23.23% | 81.85% | -31.77% | 2.81% | - | - |
Enterprise Value | 2,210 | 3,392 | 1,420 | 2,281 | 2,045 | - |
Last Close Price | 29.48 | 42.03 | 22.58 | 30.70 | 29.47 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 38.22 | 40.52 | 22.51 | 37.32 | 26.79 | - |
Forward PE | - | 12.43 | 12.43 | 21.56 | - | - |
PS Ratio | 7.52 | 9.64 | 5.39 | 9.83 | 8.65 | - |
PB Ratio | 2.13 | 3.04 | 1.70 | 2.44 | 2.38 | - |
P/TBV Ratio | 2.31 | 3.32 | 1.88 | 2.55 | 2.45 | - |
P/FCF Ratio | - | - | - | 54.27 | 45.02 | - |
P/OCF Ratio | 43.34 | 39.45 | 18.67 | 24.48 | 25.74 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 5.77 | 7.86 | 3.34 | 6.69 | 5.43 | - |
EV/EBITDA Ratio | 29.81 | 32.69 | 11.35 | 28.74 | 17.74 | - |
EV/EBIT Ratio | 48.17 | 41.17 | 13.53 | 34.50 | 19.56 | - |
EV/FCF Ratio | - | - | - | 36.93 | 28.25 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.02 |
Debt / EBITDA Ratio | 0.38 | 0.24 | 0.08 | 0.10 | 0.08 | 0.05 |
Debt / FCF Ratio | - | - | - | 0.14 | 0.13 | 0.05 |
Net Debt / Equity Ratio | -0.51 | -0.58 | -0.66 | -0.79 | -0.88 | -0.71 |
Net Debt / EBITDA Ratio | -10.00 | -7.61 | -7.07 | -13.72 | -10.46 | -2.17 |
Net Debt / FCF Ratio | 334.46 | 62.08 | 122.86 | -17.63 | -16.66 | -1.99 |
Asset Turnover | 0.25 | 0.27 | 0.28 | 0.22 | 0.38 | 0.83 |
Inventory Turnover | 1.67 | 1.81 | 1.86 | 1.60 | 2.22 | 3.10 |
Quick Ratio | 3.43 | 3.83 | 5.61 | 8.33 | 10.07 | 2.83 |
Current Ratio | 3.90 | 4.22 | 6.15 | 8.80 | 10.69 | 3.41 |
Return on Equity (ROE) | 5.17% | 7.35% | 8.00% | 6.74% | 14.84% | 38.60% |
Return on Assets (ROA) | 1.83% | 3.24% | 4.26% | 2.71% | 6.53% | 17.26% |
Return on Invested Capital (ROIC) | 7.05% | 14.84% | 24.38% | 26.78% | 68.67% | 99.19% |
Return on Capital Employed (ROCE) | 3.30% | 5.80% | 7.60% | 4.70% | 7.50% | 29.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.62% | 2.47% | 4.44% | 2.68% | 3.73% | - |
FCF Yield | -0.07% | -0.31% | -0.32% | 1.84% | 2.22% | - |
Dividend Yield | 2.71% | 1.90% | 3.54% | 1.95% | 4.41% | - |
Payout Ratio | 107.84% | 67.37% | 97.36% | 91.54% | 41.09% | 0.03% |
Buyback Yield / Dilution | 0.15% | 0.73% | 1.46% | -20.00% | -11.11% | -0.00% |
Total Shareholder Return | 2.86% | 2.63% | 5.00% | -18.04% | -6.70% | -0.00% |